Diffuse Sclerosing Papillary Carcinoma of Thyroid: A Case Report
##plugins.themes.bootstrap3.article.details##
Papillary carcinoma (PC) is the most common
malignancy neoplasm of the thyroid gland;
this carcinoma presents different histological variants, with other features and biological
behavior. In general, this condition has a good
prognosis, but the diffuse sclerosing variant is
less frequently and more aggressive. The incidence reported in the literature varies from 0.8
to 5.3% of all pediatric malignancies; this entity
is extremely rare in children under 5, with increasing frequency at a later age, mainly affecting
the children between 11-17 years. It is characterized by a diffuse involvement of one or both
lobes, sclerosis, abundant psammoma bodies,
prominent squamous metaplasia and extensive
lymphatic permeation. Patients with a large tumor
may become hoarse by pressure on the recurrent
laryngeal nerve, and have dysphagia, cough, or
airway obstruction. In this article, it presents a
case of a 18 years old patient who was performed
a total thyroidectomy with central emptying and
partial excision of the thymus. The pathological
study revealed that it was a diffuse sclerosing papillary carcinoma. Diagnostic methods, clinical
presentation and treatment are discussed
papillary carcinoma, diffuse, neoplasm, thyroid.carcinoma papilar, difuso, neoplasia, tiroides
A, Sioson L, Farzin M, et al. A detailed
clinicopathologic study of ALK-translocated
papillary thyroid carcinoma. Am J
Surg Pathol. 2015;39(5):652-9.
2. Al-Brahim N, Asa SL. Papillary thyroid
carcinoma: an overview. Arch Pathol Lab
Med. 2006;130(7):1057-62.
3. Pillai S, Gopalan V, Smith RA, Lam AK.
Diffuse sclerosing variant of papillary
thyroid carcinoma—an update of its
clinicopathological features and molecular
biology. Crit Rev Oncol Hematol.
2015;94:64-73.
4. Merino MJ. Aggressive variants of papillary
thyroid carcinoma. National Cancer
Institute. 4-13.
5. Adeniran A, Zhu Z, Gandhi M, Steward
DL, Fidler JP, Giordano TJ, et al. Correlation
between genetic alterations and
microscopic features, clinical manifestations,
and prognostic characteristics of
thyroid papillary carcinomas. Am J Surg
Pathol. 2006;30(2):216-22.
6. Carcangiu M, Bianchi S. Diffuse sclerosing
variant of papillary thyroid carcinoma:
clinicopathologic study of 15 cases.
Am J Surg Pathol. 1989;13(12):1041-9.
7. Castro Morillo AM, Castañeda Muñoz
AM, González Rodríguez D, Ríos Serrano
M, Madruga Vásquez K. Carcinoma papilar del tiroides, variante esclerosante
difusa, una de sus muchas facetas. Rev
Méd Electrón. 2014;36(5):631-5.
8. Thompson LD, Wieneke JA, Heffess CS.
Diffuse sclerosing variant of papillary
thyroid carcinoma: a clinicopathologic
and immunophenotypic analysis of 22
cases. Endocr Pathol. 2005;16(4):331-48.
9. Lam AK, Lo CY. Diffuse sclerosing
variant of papillary carcinoma of the
thyroid: a 35-year comparative study
at a single institution. Ann Surg Oncol.
2006;13:176-81.
10. Sywak M, Pasieka JL, Ogilvie T. A review
of thyroid cancer with intermediate
differentiation. J Surg Oncol. 2004;
86:44-54.
11. Koo JS, Shin E, Hong SW. Immunohistochemical
characteristics of diffuse
sclerosing variant of papillary carcinoma:
comparison with conventional papillary
carcinoma. APMIS. 2010;118(10):
744-52. doi: 10.1111/j.1600-0463.2010.
02653.x.
12. Lam AK, Lo CY, Lam KS. Papillary carcinoma
of thyroid: a 30-yr clinicopathological
review of the histological variants.
Endocr Pathol. 2005;16(4):323-30.
13. Fridman MV, Sawa NN, Krasko OV,
Zborovskaya AA, Mankovskaya SV,
Schmid KW, et al. Clinical and pathologic
features of sporadic papillary thyroid
carcinoma registered in the years 2005 to
2008 in children and adolescents of Belarus.
Thyroid. 2012;22(10):1016-24.
14. Kazaure HS, Roman SA, Sosa JA. Aggressive
variants of papillary thyroid
cancer: incidence, characteristics and
predictors of survival among 43,738
Patients. Ann Surg Oncol. 2012;19(6):
1874-80.
15. Takagi N, Hirokawa M, Nobuoka Y, Higuchi
M, Kuma S, Miyauchi A. Diffuse
sclerosing variant of papillary thyroid
carcinoma: a study of fine needle aspiration
cytology in 20 patients. Cytopathology.
2014;25(3):199-204.
16. Bongogiovanni M, Spitale A, Faquin
WC, Mazzucchelli L, Baloch ZW. The
Bethesda System for Reporting Thyroid
Cytopathology: a meta-analysis. Acta
Cytol. 2012;56(4):333-9.
17. Kwak JY, Kim EK, Hong SW, Moon
HJ, Kim MJ, Son EJ, Park CS. Diffuse
sclerosing variant of papillary carcinoma
of the thyroid gland: specimen
radiographic features with histopathological
correlation. J Clin Endocrinol Metab.
2009;94(5):1491-2. doi: 10.1210/
jc.2009-0072.
18. Nechifor-Boila A, Borda A, Sassolas G,
Hafdi-Nejjari Z, Borson-Chazot F, Lifante
JC, et al. Immunohistochemical
markers in the diagnosis of papillary
thyroid carcinomas: The promising role
of combined immunostaining using
HBME-1 and CD56. Pathol Res Pract.
2013;209(9):585-92.
19. Rosenbaum M, McHenry CR. Contemporary
management of papillary carcinoma
of the thyroid gland. Expert Rev.
Anticancer Ther. 2009;9(3):317-29.
20. Lin JD, Lin KJ, Chao TC, Hseuh C, Tsang
NM. Therapeutic outcomes of papillary
thyroid carcinomas with tumors more
advanced than T1N0M0. Radiother Oncol.
2008;89(1):97-104. doi: 10.1016/j.
radonc.2008.05.011